Asuragen at E-Conference on Chronic Myeloid Leukemia

DATE: October 7-10, 2021

Visit the Asuragen virtual booth at the 23rd Annual John Goldman e-Conference on Chronic Myeloid Leukemia to learn more about QuantideX® qPCR BCR-ABL portfolio. Targeted therapies have dramatically improved outcomes for patients with CML, who now experience a near-normal life expectancy. Optimizing these outcomes is dependent on routine, sensitive molecular monitoring. For clinicians and their patients, the best molecular results are delivered by tests with a demonstrated track record of performance.

This meeting will present the newest and often unpublished data relating to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells, approaches to cure and treatment free remission.

QuantideX® qPCR BCR-ABL Portfolio

The QuantideX qPCR BCR-ABL IS Kit’s unprecedented level of sensitivity coupled to a simple-to-run, singlicate test, allows labs to reliably and reproducibly monitor much deeper molecular response.